BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Friedman SL, Pinzani M. Hepatic fibrosis 2022: Unmet needs and a blueprint for the future. Hepatology 2022;75:473-88. [PMID: 34923653 DOI: 10.1002/hep.32285] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Dai Y, Zhao Z, Liu C. Treatment of Liver Fibrosis: A 20-Year Bibliometric and Knowledge-Map Analysis. Front Pharmacol 2022;13:942841. [DOI: 10.3389/fphar.2022.942841] [Reference Citation Analysis]
2 Yan J, Liu Q, Tang Q, Zhang J, Jing X, Xia Y, Xu Y, Li J, Li Y, He J. Mesencephalic astrocyte-derived neurotrophic factor alleviates non-alcoholic steatohepatitis induced by Western diet in mice. FASEB J 2022;36:e22349. [PMID: 35567505 DOI: 10.1096/fj.202101975R] [Reference Citation Analysis]
3 Chen X, Wang Y, Ji S, Sun X, Feng Q, Yu H, Liu C. Hepatoprotective Efficacy and Interventional Mechanism of Qijia Rougan Decoction in Liver Fibrosis. Front Pharmacol 2022;13:911250. [DOI: 10.3389/fphar.2022.911250] [Reference Citation Analysis]
4 Amer MA, Othman AI, El-Missiry MA, Farag AA, Amer ME. Proanthocyanidins attenuated liver damage and suppressed fibrosis in CCl4-treated rats. Environ Sci Pollut Res Int 2022. [PMID: 35881285 DOI: 10.1007/s11356-022-22051-7] [Reference Citation Analysis]
5 Kimura K, Kanto T, Shimoda S, Harada K, Kimura M, Nishikawa K, Imamura J, Ogawa E, Saio M, Ikura Y, Okusaka T, Inoue K, Ishikawa T, Ieiri I, Kishimoto J, Todaka K, Kamisawa T. Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study. EBioMedicine 2022;80:104069. [PMID: 35605429 DOI: 10.1016/j.ebiom.2022.104069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Vu Ngoc H, Thuy LTT, Hai H, Dat NQ, Hoang DV, Hanh NV, Phuong DM, Hoang TH, Sawai H, Shiro Y, Sato-matsubara M, Oikawa D, Tokunaga F, Yoshizato K, Kawada N. Capacity of extracellular globins to reduce liver fibrosis via scavenging reactive oxygen species and promoting MMP-1 secretion. Redox Biology 2022. [DOI: 10.1016/j.redox.2022.102286] [Reference Citation Analysis]
7 Luo N, Zhong W, Li J, Lu J, Dong R. CRISPR/dCas9 for hepatic fibrosis therapy: implications and challenges. Mol Biol Rep 2022. [PMID: 35960410 DOI: 10.1007/s11033-022-07713-6] [Reference Citation Analysis]
8 Qian K, Lei X, Liu G, Fang Y, Xie C, Wu X, Liu Q, Liu G, Cao Z, Zhang J, Kuang T, Yan L, Fu J, Du H, Liu Z, Chu Y, Xu G, Yamamoto H, Mori M, Liang XM, Xu X, Sun Y. Transient Receptor Potential Vanilloid-1 (TRPV1) Alleviates Hepatic Fibrosis via TGF-β Signaling. Disease Markers 2022;2022:1-15. [DOI: 10.1155/2022/3100943] [Reference Citation Analysis]
9 Xin Y, Liu F, Li D, Zhu J. Viscoelasticity assessment for in vivo quantification of muscle contusion injury in rats using shear wave elastography. Ultrasound Med Biol 2022:S0301-5629(22)00416-1. [PMID: 35868906 DOI: 10.1016/j.ultrasmedbio.2022.05.026] [Reference Citation Analysis]
10 Weiskirchen R. Special Issue on “Cellular and Molecular Mechanisms Underlying the Pathogenesis of Hepatic Fibrosis II”. Cells 2022;11:2403. [DOI: 10.3390/cells11152403] [Reference Citation Analysis]